Odyssey Therapeutics, Inc. Preferred Shares: Authorized and Outstanding
The company's filed XBRL preferred stock facts (us-gaap Preferred*), one row per period end, newest first. Values are as filed.
- 2026-06-30: Preferred Stock, Value, Issued $0.00; Preferred Stock, Par or Stated Value Per Share $0.00; Preferred Stock, Shares Authorized 50.00M shares; Preferred Stock, Shares Issued 0.00 shares.
- 2026-03-31: Preferred Stock, Shares Authorized 237.27M shares; Preferred Stock, Shares Issued 237.19M shares.
- 2025-12-31: Preferred Stock, Value, Issued $0.00; Preferred Stock, Par or Stated Value Per Share $0.00; Preferred Stock, Shares Authorized 0.00 shares; Preferred Stock, Shares Issued 0.00 shares.
| Period end | Preferred Stock, Value, Issued | Preferred Stock, Par or Stated Value Per Share | Preferred Stock, Shares Authorized | Preferred Stock, Shares Issued | Preferred Stock, Shares Outstanding |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | 50.00M shares 10-Q · filed 2026-08-06 | 0.00 shares 10-Q · filed 2026-08-06 | 0.00 shares 10-Q · filed 2026-08-06 |
| 2026-03-31 | 237.27M shares 10-Q · filed 2026-06-17 | 237.19M shares 10-Q · filed 2026-06-17 | 237.19M shares 10-Q · filed 2026-06-17 | ||
| 2025-12-31 | $0.00 10-Q · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | 0.00 shares 10-Q · filed 2026-08-06 | 0.00 shares 10-Q · filed 2026-08-06 | 0.00 shares 10-Q · filed 2026-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |